Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Net Margin (2019 - 2026)

C4 Therapeutics has reported Net Margin over the past 8 years, most recently at 408.47% for Q1 2026.

  • For Q1 2026, Net Margin fell 4480.0% year-over-year to 408.47%; the TTM value through Mar 2026 reached 297.41%, down 3781.0%, while the annual FY2025 figure was 292.08%, 388.0% up from the prior year.
  • Net Margin for Q1 2026 was 408.47% at C4 Therapeutics, down from 184.87% in the prior quarter.
  • Over five years, Net Margin peaked at 147.56% in Q2 2024 and troughed at 1348.42% in Q2 2023.
  • A 5-year average of 560.14% and a median of 408.47% in 2026 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: plummeted -122492bps in 2022 and later surged 120086bps in 2024.
  • Year by year, Net Margin stood at 1302.91% in 2022, then grew by 18bps to 1065.84% in 2023, then soared by 37bps to 667.82% in 2024, then surged by 72bps to 184.87% in 2025, then crashed by -121bps to 408.47% in 2026.
  • Business Quant data shows Net Margin for CCCC at 408.47% in Q1 2026, 184.87% in Q4 2025, and 286.43% in Q3 2025.